Fox Chase Cancer Center News

Choice of First-Line Platinum Regimen Does Not Significantly Impact Efficacy of Second-Line Immunotherapy in Advanced Bladder Cancer

PHILADELPHIA (June 3, 2021) – In a presentation of real-world data, researchers from Fox Chase Cancer Center have concluded that the choice of first-line platinum chemotherapy did not result in a significant difference in overall survival benefit among patients with advanced bladder cancer who were able to go on to receive second-line immunotherapy.

VIEW STORY